Inhibition of proliferation of prostate cancer cell line DU-145 in vitro and in vivo using Salvia miltiorrhiza Bunge.

  • Woong Jin Bae
  • Jin Bong Choi
  • Kang Sup Kim
  • U. Syn Ha
  • Sung Hoo Hong
  • Ji Youl Lee
  • Tae-Kon Hwang
  • Sung Yeoun Hwang
  • Zhi-ping Wang
  • Sae Woong KimEmail author
Original Article



To investigate the antiproliferative activity of Salvia miltiorrhiza Bunge. (SM) on the castration-resistant prostate cancer (CRPC) cell line DU-145, in vitro and in vivo.


Prostate cancer cell line (DU-145) and normal prostate cell line (RWPE-1) were treated with SM at different concentrations (3.125, 12.5, 25 and 50 μg/mL) to investigate the antiproliferative effects. DNA laddering analysis was performed to investigate the apoptosis of DU-145 cells. Molecular mechanism was investigated by Western blot analysis of p53, Bcl-2, prostate specific antigen (PSA), and androgen receptor (AR). Six-week-old male BALB/c nude mice were randomly divided into normal control group (n=101) and treated group (n=101) which administered 500 mg/kg SM for 2 weeks. Tumor volumes were measured.


Treatment with SM resulted in a dose-dependent decrease in cell number of DU-145 cells in comparison with RWPE-1. DNA laddering analysis indicated the apoptosis of DU-145 cells. Treatment with SM increased the expression of p53 and reduced the expression of Bcl-2 proteins. The levels of PSA were considerably reduced in SM-treated group compared to the controls, and a decrease in AR expression was observed when cells were treated with SM in the same pattern as a reduction in PSA. In the tumour xenograft study, SM given once a day for 2 weeks significantly inhibited tumour growth.


SM might contribute to the anticancer actions such as induction of apoptosis and inhibition of proliferation of prostate cancer cells.


apoptosis prostate cancer Salvia miltiorrhiza Bunge. 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Grönberg H. Prostate cancer epidemiology. Lancet 2003;361:859–864.CrossRefPubMedGoogle Scholar
  2. 2.
    Won YJ, Sung J, Jung KW, Kong HJ, Park S, Shin HR, et al. Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat 2009;41:122–131.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, et al. Rising prostate cancer rates in South Korea. Prostate 2006;66:1285–1291.CrossRefPubMedGoogle Scholar
  4. 4.
    Von Löw EC, Perabo FG, Siener R, Müller SC. Review. Facts and fiction of phytotherapy for prostate cancer: a critical assessment of preclinical and clinical data. In Vivo 2007;21:189–204.Google Scholar
  5. 5.
    Kim SJ, Kim SI. Current treatment strategies for castrationresistant prostate cancer. Korean J Urol 2011;52:157–165.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572–583.CrossRefPubMedGoogle Scholar
  7. 7.
    Van Allen EM, Ryan CJ. Novel secondary hormonal therapy in advanced prostate cancer: an update. Curr Opin Urol 2009;19:315–321.CrossRefPubMedGoogle Scholar
  8. 8.
    Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000;14:2410–2434.CrossRefPubMedGoogle Scholar
  9. 9.
    Cohen JH, Kristal AR, Stanford JL. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 2000;92:61–68.CrossRefPubMedGoogle Scholar
  10. 10.
    Liu E, Wu J, Cao W, Zhang J, Liu W, Jiang X, et al. Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. J Neurooncol 2007;85:263–270.CrossRefPubMedGoogle Scholar
  11. 11.
    Gallo D, Zannoni GF, De Stefano I, Mosca M, Ferlini C, Mantuano E, et al. Soy phytochemicals decrease nonsmall cell lung cancer growth in female athymic mice. J Nutr 2008;138:1360–1364.PubMedGoogle Scholar
  12. 12.
    Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 2005;45:1345–1359.CrossRefPubMedGoogle Scholar
  13. 13.
    Cheng TO. Cardiovascular effects of Danshen. Int J Cardiol 2007;121:9–22.CrossRefPubMedGoogle Scholar
  14. 14.
    Wang X, Morris-Natschke SL, Lee KH. New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med Res Rev 2007;27:133–148.CrossRefPubMedGoogle Scholar
  15. 15.
    Alessandri G, Filippeschi S, Sinibaldi P, Mornet F, Passera P, Spreafico F, et al. Influence of gangliosides on primary and metastatic neoplastic growth in human and murine cells. Cancer Res 1987;47:4243–4247.PubMedGoogle Scholar
  16. 16.
    Liu JJ, Liu WD, Yang HZ, Zhang Y, Fang ZG, Liu PQ, et al. Inactivation of PI3k/Akt signaling pathway and activation of caspase-3 are involved in tanshinone I-induced apoptosis in myeloid leukemia cells in vitro. Ann Hematol 2010;89:1089–1097.CrossRefPubMedGoogle Scholar
  17. 17.
    Lee CY, Sher HF, Chen HW, Liu CC, Chen CH, Lin CS, et al. Anticancer effects of tanshinone I in human non-small cell lung cancer. Mol Cancer Ther 2008;7:3527–3538.CrossRefPubMedGoogle Scholar
  18. 18.
    Suh SJ, Jin UH, Choi HJ, Chang HW, Son JK, Lee SH, et al. Cryptotanshinone from Salvia miltiorrhiza Bunge has an inhibitory effect on TNF-alpha-induced matrix metalloproteinase-9 production and HASMC migration via down-regulated NF-kappaB and AP-1. Biochem Pharmacol 2006;72:1680–1689.CrossRefPubMedGoogle Scholar
  19. 19.
    Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996;87:629–638.CrossRefPubMedGoogle Scholar
  20. 20.
    Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996;2:277–285.PubMedGoogle Scholar
  21. 21.
    Linja MJ, Savinainen KJ, Saramäki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550–3555.PubMedGoogle Scholar
  22. 22.
    Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, et al. A mechanism for androgen receptormediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315–4319.PubMedGoogle Scholar
  23. 23.
    Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276–308.CrossRefPubMedGoogle Scholar
  24. 24.
    Singh P, Uzgare A, Litvinov I, Denmeade SR, Isaacs JT. Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr Relat Cancer 2006;13:653–666.CrossRefPubMedGoogle Scholar
  25. 25.
    Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006;12:1665–1671.CrossRefPubMedGoogle Scholar
  26. 26.
    Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787–790.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301:39–51.CrossRefPubMedGoogle Scholar
  28. 28.
    Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215–224.CrossRefPubMedGoogle Scholar
  29. 29.
    Gomella LG. Chemoprevention using dutasteride: the REDUCE trial. Curr Opin Urol 2005;15:29–32.CrossRefPubMedGoogle Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine and Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Woong Jin Bae
    • 1
    • 2
  • Jin Bong Choi
    • 1
  • Kang Sup Kim
    • 1
  • U. Syn Ha
    • 1
  • Sung Hoo Hong
    • 1
  • Ji Youl Lee
    • 1
  • Tae-Kon Hwang
    • 1
  • Sung Yeoun Hwang
    • 3
  • Zhi-ping Wang
    • 4
  • Sae Woong Kim
    • 1
    • 2
    Email author
  1. 1.Department of UrologyThe Catholic University of Korea, College of MedicineSeoulRepublic of Korea
  2. 2.Catholic Integrative Medicine Research InstituteCollege of Medicine, The Catholic University of KoreaSeoulRepublic of Korea
  3. 3.Korea Bio-Medical Science InstituteSeoulRepublic of Korea
  4. 4.Department of UrologySecond Hospital of Lanzhou UniversityLanzhouChina

Personalised recommendations